Good Life Advisors LLC Sells 139 Shares of Becton, Dickinson and Company (NYSE:BDX)

Good Life Advisors LLC reduced its position in Becton, Dickinson and Company (NYSE:BDX) by 12.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,006 shares of the medical instruments supplier’s stock after selling 139 shares during the quarter. Good Life Advisors LLC’s holdings in Becton, Dickinson and Company were worth $228,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Brighton Jones LLC boosted its stake in shares of Becton, Dickinson and Company by 98.2% in the 4th quarter. Brighton Jones LLC now owns 1,770 shares of the medical instruments supplier’s stock valued at $401,000 after purchasing an additional 877 shares in the last quarter. E. Ohman J or Asset Management AB boosted its stake in shares of Becton, Dickinson and Company by 13.4% in the 4th quarter. E. Ohman J or Asset Management AB now owns 176,097 shares of the medical instruments supplier’s stock valued at $39,951,000 after purchasing an additional 20,859 shares in the last quarter. Arete Wealth Advisors LLC acquired a new stake in shares of Becton, Dickinson and Company in the 3rd quarter valued at approximately $767,000. Busey Bank boosted its stake in shares of Becton, Dickinson and Company by 3.8% in the 4th quarter. Busey Bank now owns 66,255 shares of the medical instruments supplier’s stock valued at $15,031,000 after purchasing an additional 2,399 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of Becton, Dickinson and Company by 79.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 2,986,543 shares of the medical instruments supplier’s stock valued at $720,089,000 after purchasing an additional 1,317,723 shares in the last quarter. 86.97% of the stock is owned by institutional investors.

Analysts Set New Price Targets

A number of equities research analysts have recently weighed in on the stock. Barclays raised their price target on shares of Becton, Dickinson and Company from $278.00 to $279.00 and gave the company an “overweight” rating in a research note on Friday, February 14th. StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a research report on Wednesday, February 12th. Finally, Piper Sandler lifted their target price on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 28th. Eight research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $278.29.

Becton, Dickinson and Company Stock Down 0.2 %

NYSE:BDX opened at $227.54 on Friday. The firm’s 50 day simple moving average is $232.90 and its 200 day simple moving average is $233.29. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.13 and a quick ratio of 0.63. Becton, Dickinson and Company has a one year low of $218.75 and a one year high of $251.99. The company has a market cap of $65.34 billion, a PE ratio of 37.80, a P/E/G ratio of 1.63 and a beta of 0.40.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. On average, research analysts anticipate that Becton, Dickinson and Company will post 14.43 earnings per share for the current year.

Becton, Dickinson and Company Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Monday, March 31st. Stockholders of record on Monday, March 10th will be given a $1.04 dividend. The ex-dividend date is Monday, March 10th. This represents a $4.16 dividend on an annualized basis and a dividend yield of 1.83%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is currently 69.10%.

Becton, Dickinson and Company announced that its board has authorized a stock repurchase plan on Tuesday, January 28th that authorizes the company to repurchase 10,000,000 shares. This repurchase authorization authorizes the medical instruments supplier to buy shares of its stock through open market purchases. Stock repurchase plans are generally a sign that the company’s leadership believes its stock is undervalued.

Insider Transactions at Becton, Dickinson and Company

In other news, EVP Shana Carol Neal sold 788 shares of the business’s stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $235.00, for a total value of $185,180.00. Following the transaction, the executive vice president now owns 16,201 shares in the company, valued at approximately $3,807,235. The trade was a 4.64 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Roland Goette sold 4,483 shares of Becton, Dickinson and Company stock in a transaction on Friday, December 6th. The shares were sold at an average price of $221.01, for a total transaction of $990,787.83. Following the completion of the sale, the executive vice president now owns 24,345 shares of the company’s stock, valued at $5,380,488.45. This represents a 15.55 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 10,544 shares of company stock worth $2,370,309. Company insiders own 0.36% of the company’s stock.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.